EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis

Mohammed Nabil Quraishi iD, Maryam A Alahmad, Thaer Khaleel Swaid, Antonio Facciorusso, Alyssa A Grimshaw, Badr Al-Bawardy iD

Inflammatory Bowel Diseases · 2026

DOI: 10.1093/ibd/izag032 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Mohammed Nabil Quraishi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Sheikh Shakhbout Medical City, Pure Health, Abu Dhabi, United Arab Emirates. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Acne Vulgaris, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 75 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Janus kinase (JAK) inhibitors are effective oral therapies for inflammatory bowel disease (IBD). While acne is a known adverse event in dermatological cohorts, its incidence and risk factors in the IBD population are not well-defined. We aimed to determine the pooled incidence of acne in IBD patients treated with JAK inhibitors and to explore this risk across key clinical subgroups.

Methods

We conducted a systematic review and meta-analysis following PRISMA guidelines. MEDLINE, EMBASE, and CENTRAL were searched from inception to September 2025 for randomized controlled trials (RCTs) and observational studies reporting acne incidence in IBD patients on JAK inhibitors. Data were pooled using a random-effects generalized linear mixed-effects model. Pre-specified subgroup analyses were performed.

Results

A total of 50 studies (5 RCTs, 45 observational) involving 9902 IBD patients were included. The overall pooled incidence of acne was 8.6% (95% CI: 6.4%-11.6%). Acne rates were significantly higher (P < .0001) with the upadacitinib (12.2%), compared to tofacitinib (2.6%) and filgotinib (2.3%). A numerically higher incidence was observed during induction (8.6%) versus maintenance (4.2%) therapy, though this difference was not statistically significant (P = .07). The incidence was significantly higher in the pediatric population (12.2%) compared to adults (7.4%) (P = .03). In RCTs, JAK inhibitors were associated with significantly increased odds of acne compared to placebo (OR 2.43, 95% CI: 1.33-4.43, P = .019). No statistically significant difference was observed by IBD subtype.

Conclusion

Acne is a common adverse event in IBD patients treated with JAK inhibitors. The reported incidence of acne was significantly higher with upadacitinib, in the pediatric population, and numerically higher during the induction phase of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsAcne VulgarisInflammatory Bowel DiseasesHumansIncidenceHeterocyclic Compounds, 3-RingPyrimidinesPiperidinesPyridinesTriazoles

Stichwörter der Autor:innen

Crohn’s diseaseIBDJAK inhibitoracneulcerative colitis

Substanzen

Janus Kinase InhibitorsHeterocyclic Compounds, 3-RingupadacitinibPyrimidinestofacitinibGLPG0634PiperidinesPyridinesTriazoles

Autor:innen und Institutionen

  • Department of Gastroenterology, Sheikh Shakhbout Medical City, Pure Health, Abu Dhabi, United Arab Emirates.
  • Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.
  • College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.
  • Gastroenterology Unit, Department of Experimental Medicine, Università del Salento, Lecce, Italy.
  • Harvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven, CT, United States.
  • Department of Gastroenterology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

ORCID-Profile: Mohammed Nabil Quraishi, Badr Al-Bawardy

Zitieren

APA

Quraishi, M. N., Alahmad, M. A., Swaid, T. K., Facciorusso, A., Grimshaw, A. A., & Al-Bawardy, B. (2026). Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag032

Vancouver

Quraishi MN, Alahmad MA, Swaid TK, Facciorusso A, Grimshaw AA, Al-Bawardy B. Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag032

BibTeX
@article{Quraishi2026,
  author = {Quraishi, Mohammed Nabil and Alahmad, Maryam A and Swaid, Thaer Khaleel and Facciorusso, Antonio and Grimshaw, Alyssa A and Al-Bawardy, Badr},
  title = {Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  doi = {10.1093/ibd/izag032}
}
Kostenlos starten →